1[2]Bristow MR, David Port J ,Kelly RA. Principles of pharmacologic management of chronic heart failure. In: Antman EM. Cardiovascular therapeutics. 2nd ed. Philadelphia: WB Saunders Co. ,2002. 300-324.
2[3]McClean DR, Ikram H, Garlick AH, et al. The clinical,cardiac, renal, arterial and neurohormonal effects of omapatrilat, a vasopeptidase inhibitor in patients with chronic heart failure. J Am Coll Cardiol, 2000, 36:479-486.
3[4]Aukrust P, Ueland T, Lien E, et al. Cytokine network in congestive heart failure secondary to ischemic or idiopathic dilated cardiomyopathy. Am J Cardiol, 1999,83:376-378.
4[5]Bozkurt B, Torre-Amione G, Warren MS, et al. Results of targeted anti-tumor necrosis factor therapy with etanercept (Enbrel) in patients with advanced heart failure. Circulation, 2001,103:1044-1047.
8Themas TA, Marks BH. Plasma nortpinephin in congestive heart failure [J]. Am J Cardial, 2002, 41 (2) : 233.
9Schepkens H, Vanholder R, Billiouw JM, et al. Life-threatening hyperkalemia during combined therapy with angiotensin-convetting enzyme inhibitors and spironolactone: an analysis of 25 cases [J]. AMJMed, 2001, 110 (6): 4
10Charlap S, Lichstein E, William H, et al. Adrenergic blocking drug in the tneatment of Congestive heart failure [J]. Med Cli - North Atn, 2001, 73 (27): 373.
